Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Susannah Johnson

Internal Medicine New Bern, NC Medical Doctor

NPI 1750606075 CMS profile 1238818

2604 Dr Martin Luther King Jr Blvd, New Bern, NC 28562

Open in the dashboard

General payments

$2,962

197 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susannah Johnson of New Bern, NC is reported in the CMS Open Payments database as having received $2,962 across 197 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $106 6
2024 General $1,440 94
2023 General $917 60
2022 General $320 25
2021 General $178 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susannah Johnson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Susannah Johnson were reported at $106. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Susannah Johnson Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $178 $135 $37–$521 $132
2022 $320 $141 $42–$496 $149
2023 $917 $149 $45–$519 $160
2024 $1,440 $154 $47–$537 $164
2025 $106 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $754 61 payments
  2. GlaxoSmithKline, LLC. $499 44 payments
  3. Novartis Pharmaceuticals Corporation $433 29 payments
  4. AstraZeneca Pharmaceuticals LP $387 5 payments
  5. Lilly USA, LLC $199 13 payments
  6. Daiichi Sankyo Inc. $194 12 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $121 9 payments
  8. Amgen Inc. $100 7 payments
  9. Novo Nordisk Inc $80 5 payments
  10. Eisai Inc. $76 4 payments
  11. Other $119 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,942 196 payments
  2. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. Kerendia $754 61 payments
  2. LEQVIO $387 26 payments
  3. FARXIGA $358 3 payments
  4. TRELEGY ELLIPTA $336 37 payments
  5. BREZTRI $285 4 payments
  6. MOUNJARO $199 13 payments
  7. INJECTAFER $194 12 payments
  8. AIRSUPRA $171 1 payment
  9. AREXVY $160 7 payments
  10. ENTRESTO $146 13 payments
  11. Other $752 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 148 drugs

Part D claims

9,592

Median for Internal Medicine: 777

Drug cost

$1,473,666

Median for Internal Medicine: $73,373

Branded share of claims

23.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 165 $213,074
Farxiga Dapagliflozin Propanediol Brand 178 $182,930
Ozempic Semaglutide Brand 108 $137,625
Kerendia Finerenone Brand 93 $114,565
Trulicity Dulaglutide Brand 97 $114,389
Eliquis Apixaban Brand 114 $104,112
Jardiance Empagliflozin Brand 100 $99,173
Rybelsus Semaglutide Brand 56 $71,157
Entresto Sacubitril/Valsartan Brand 46 $70,870
Januvia Sitagliptin Phosphate Brand 58 $62,669

The 10 drugs with the highest cost, of 148 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 132 billing codes

Paid by Medicare

$171,703

Of which drugs: $71,182

Medicare patients

319

Average age 73

Services billed

13,387

236 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 45%
Diabetes 35%
Depression 23%
Atrial fibrillation 20%
COPD 20%
Osteoporosis 20%
Ischemic heart disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 44 45 $3,593
Injection, methylprednisolone acetate, 1 mg J1010 Office 22 1,240 $127
Injection, ketorolac tromethamine, per 15 mg J1885 Office 21 94 $35
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 12 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $299
$299 93 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $271
$271 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $150
$150 66 —
AREXVY
  • GlaxoSmithKline, LLC. $135
$135 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record